Skip to content

Aurion Biotech to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) and Ophthalmology European Futures Forum

Presentations at conferences will feature clinical data and business updates on Aurion Biotech’s allogeneic cell therapy AURN001 for the treatment of corneal endothelial diseases

Seattle, WA; Cambridge, MA; Tokyo, Japan – September 3, 2024 – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it will present clinical data on its allogeneic cell therapy drug candidate, AURN001, at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS 2024) to be held September 6-10, 2024 in Barcelona, Spain. Aurion Biotech also will present and participate in several panel discussions during the Ophthalmology Futures European Forum, which takes place September 5th in Barcelona.

“We are thrilled to share clinical findings, as well as clinical and business milestones in multiple sessions at ESCRS and the Ophthalmology Futures European Forum,” said Dr. Michael Goldstein, president and chief medical Officer. “In particular, we believe that efficacy and safety data from the Escalón clinical trial provide additional insights into how our combination drug candidate may have a positive impact on the lives of patients suffering from corneal endothelial dysfunction.” The schedule of presentations is as follows:

Ophthalmology Futures European Forum

  • Will Novel Dry Eye Therapies Really Make a Difference?
    • Thursday, September 5, 2024
    • 1:15 p.m. – 1:45 p.m. CET
    • The Esferic, Barcelona
    • Panelist: Michael Goldstein, MD, MBA, President and Chief Medical Officer
  • Cell, Gene and other Novel Corneal Therapies: Outlook for the Second Quarter of the 21st Century
    • Thursday, September 5, 2024
    • 1:45 p.m. – 2:15 p.m. CET
    • The Esferic, Barcelona
    • Panelist: Greg Kunst, Chief Executive Officer
  • Transformational Cell Therapy for Corneal Endothelial Disease
    • Thursday, September 5, 2024
    • 2:30 p.m. – 3:15 p.m. CET
    • The Esferic, Barcelona
    • Presenter: Greg Kunst, Chief Executive Officer
  • Patient- vs. Provider-Centric Biotech & MedTech Innovation
    • Thursday, September 5, 2024
    • 6:45 p.m. – 7:15 p.m. CET
    • The Esferic, Barcelona
    • Panelist: Eris Jordan, OD, Vice President, Global Clinical & Medical Affairs

ESCRS iNovation Day

  • Transformational Cell Therapy for Corneal Endothelial Disease
    • Friday, September 6, 2024
    • 11:26 a.m. – 12:23 p.m. CET
    • Fira Gran Via, Barcelona
    • Presenter: Greg Kunst, Chief Executive Officer

ESCRS

Aurion Biotech’s drug candidate, AURN001, recently received both Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation from the U.S. Food and Drug Administration for the treatment of corneal edema secondary to corneal endothelial disease. In Japan, Aurion has received both regulatory and reimbursement approval for the treatment of bullous keratopathy, marking the first-ever approval in the world for an allogeneic cell therapy to treat corneal endothelial disease.

About Aurion Biotech

Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. It received the prestigious Prix Galien award for best start-up in biotech. Its first candidate is for the treatment of corneal edema secondary to corneal endothelial disease, and the first clinically validated cell therapy for corneal care, having received regulatory approval in Japan. The Company has completed enrollment and dosing of its Phase 1 / 2  clinical trial in the U.S. and Canada. Privately held, Aurion Biotech is backed by Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures. To learn more, visit www.aurionbiotech.com

[1] https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation

[2] https://aurionbiotech.com/aurion-biotech-announces-completion-of-enrollment-in-phase-1-2-clinical-trial